Last updated: 11/07/2018 14:46:19
Investigation of the effects of the thiazolidinedione, rosiglitazone, on regional adiposity, intrahepatic fat and muscle insulin sensitivity in type 2 diabetic patients (TRIM)
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Investigation of the effects of the thiazolidinedione, rosiglitazone, on regional adiposity, intrahepatic fat and muscle insulin sensitivity in type 2 diabetic patients (TRIM)
Trial description: Investigation of the effects of the thiazolidinedione, rosiglitazone, on regional adiposity, intrahepatic fat and muscle insulin sensitivity in type 2 diabetic patients (TRIM)
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Carey DG et al. Rosiglitazone: positive effects on visceral fat and insulin sensitivity in NIDDM. Abs presented at the Australian Diabetes Society Conference, August 2000, Cairns.
Carey DG, Cowin GJ, Galloway GJ et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res 2002; 10:1008–1015.
Carey DG, Cowin GJ, Galloway GJ et al. Rosiglitazone improves insulin sensitivity and decreases hepatic fat in patients with type 2 diabetes Abs and poster P0645A presented at ICE 2000.
Carey DG, Cowin GJ, Galloway GJ et al. Rosiglitazone increases insulin sensitivity and reduces factors associated with insulin resistance in type 2 diabetics. Diabetes Res Clin Pract 2000; 50 (Suppl 1):P311. Abs and poster presented at IDF 2000.
Carey DG, Galloway G, Dodrell D et al. Rosiglitazone reduces hepatic fat and increases subcutaneous but not intra-abdominal fat depots. Diabetologia 2000; 43 (Suppl 1):A68. Abs 271 presented at EASD 2000.
Cobitz A, Deacon L, Stewart M. Rosiglitazone: effects on the insulin resistance metabolic syndrome. Can J Diabetes Care 2001; 25 (3). Poster 170 presented at the 5th Annual CDA/CSEM Professional Conference 2001.
Garber A, Cobitz AR, Deacon L et al. Rosiglitazone: effects on the insulin resistance metabolic syndrome. Abs 36051 and poster P3-61 presented at ENDO 2001.
Medical condition
Diabetes Mellitus, Type 2
Product
rosiglitazone
Collaborators
Not applicable
Study date(s)
November 1998 to October 1999
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1999-05-10
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website